EVO Stock Analysis: Buy, Sell, or Hold?
EVO - Evotec SE American Depositary Shares
$2.86
0.06 (1.96%)
▲
5d:
+6.13%
30d:
-7.0%
90d:
+14.2%
BUY
HIGH Confidence
Analysis Updated: Jun 30, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When EVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: EVO shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: EVO shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: EVO is currently trading at $2.85, which is considered fair relative to its 30-day fair value range of $2.65 to $2.93. From a valuation perspective, the stock is trading at a discount (Forward PE: -18.1) compared to its historical average (45.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, EVO is in a downtrend. The price is approaching resistance at $2.85. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: EVO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.10 (+82.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EVO is in a downtrend. The price is approaching resistance at $2.85. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: EVO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.10 (+82.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.65 -
$2.93
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
88.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 82.3% below Wall St target ($5.10)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$2.65 -
$2.93
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.56
Resistance Level
$2.85
Current Trend
Downtrend
Technical data as of
Jun 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-18.06
Wall Street Target
$5.10
(+82.3%)
Revenue Growth (YoY)
-21.7%
Profit Margin
-26.0%
PE vs Historical
-18.1 vs 45.3
CHEAP
Share & Embed Analysis
Last updated: July 01, 2026 12:08 PM ET
Data refreshes hourly during market hours. Next update: 1:08 PM
Data refreshes hourly during market hours. Next update: 1:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 64 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 57 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 62 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 61 BUY |
